Erika Smith, CEO of New Haven’s ReNetX Bio, has joined the board of directors at BioCT, the state’s bioscience advocacy organization.
ReNetX is a clinical-stage, venture-funded bioscience company that is working on a treatment to reverse spinal cord injury. Prior to leading ReNetX, Smith has held key executive roles at leading life-science companies including Respironics (Philips Healthcare), Hyperion and IVAX, BioCT said.
She also launched and led the advancement of three successful investment funds, including the $25 million Blavatnik Fund for Innovation at Yale, the Yale Entrepreneurial Institute Innovation Fund and the Bio-Life Fund at the Center for Innovative Technology in partnership with Johnson & Johnson.
Smith was highlighted in New Haven Biz’s special Innovators & Entrepreneurs publication in September 2019.
